Remdesivir Rivals Hit Indian Market
Hetero And Cipla's Versions Launched, 'Surplus' Envisaged By August
Executive Summary
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
You may also be interested in...
'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains
The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.
Mylan Has Green Light On Remdesivir
Lauding a “significant milestone for Mylan, for the global public health community and, most importantly, for patients who are battling this pandemic,” Mylan has received approval in India for its remdesivir 100mg/vial product licensed from Gilead Sciences.
Remdesivir Compulsory Licensing Is A Dead End For Europe
In the wake of the revelation that the US has secured rights to almost all of Gilead’s remdesivir supplies through September 2020, compulsory licensing had been raised as a possible way for countries to procure versions of the COVID-19 treatment. However, Medicines for Europe has cautioned that the procedure will not be practical to apply in Europe.